PFE Jan 2024 35.000 call
| Previous Close | 15.75 |
| Open | 14.90 |
| Bid | 14.60 |
| Ask | 14.95 |
| Strike | 35.00 |
| Expire Date | 2024-01-19 |
| Day's Range | 14.90 - 14.90 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 758 |
- Motley Fool
Better Buy: Novavax or BioNTech Stock?
The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.
- Reuters
UPDATE 1-China's CanSino confident its mRNA COVID vaccine as good as Moderna, Pfizer shots
CanSino Biologics Chief Executive Yu Xuefeng said on Friday he was confident his company's experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech. As the COVID-19 pandemic evolves in China after the country abandoned its zero-COVID policy in December, domestic companies like CanSino are racing to develop mRNA COVID vaccines. The country - which experienced a wave of infections across its 1.4 billion population after the sudden relaxation of COVID restrictions - has so far declined to use mRNA vaccines from abroad, and has yet to approve a domestic one that uses the technology.
- Reuters
China's CanSino confident its mRNA COVID vaccine as good as Moderna, Pfizer shots
CanSino Biologics CEO Yu Xuefeng said on Friday he was confident his company's experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech. As the COVID-19 pandemic evolves in China after the country abandoned its zero-COVID policy in December, domestic companies like CanSino are racing to develop mRNA COVID vaccines. The country - which experienced a wave of infections across its 1.4 billion population after the sudden relaxation of COVID restrictions - has so far declined to use mRNA vaccines from abroad, and has yet to approve a domestic one that uses the technology.
